FindTrial
Sign In

Effect of pegylated recombinant human granulocyte colony stimulating factor on lymphocytes of patients with malignant tumors

Effect of pegylated recombinant human granulocyte colony stimulating factor on lymphocytes of patients with malignant tumors

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200063211
Enrollment
Unknown
Registered
2022-09-01
Start date
2022-09-01
Completion date
Unknown
Last updated
2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cancer

Interventions

control group :pegylated recombinant human granulocyte stimulating factor 6mg subcutaneously, once every 3 weeks

Sponsors

Department of Oncology, the Eighth People's Hospital of Jinan
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Histopathologically or cytologically confirmed malignant tumors; 2. No hematologic system diseases; 3. Aged >= 18 years; 4. ECOG PS score less than or equal to 2; 5. Before Chemotherapy, white blood cell (WBC) >= 4.0 x 10^9/L, absolute neutrophil count (ANC) >= 2.0 x 10^9/L, hemoglobin (Hb) >= 9.0 g/dL, platelets (PLT) >= 80 x 10^9/L; 6. Normal coagulation function; 7. Normal heart, liver and kidney function.

Exclusion criteria

Exclusion criteria: 1. Repeated myelosuppression in previous chemotherapy; 2. Uncontrollable infection; 3. Previous hematopoietic stem cell transplantation or organ transplantation; 4. Previous radiotherapy treatment; 5. Presence of bone marrow invasion; 6. Combined with other serious complications.

Design outcomes

Primary

MeasureTime frame
Changes in the number of lymphocytes;—

Countries

China

Contacts

Public ContactZhang Weike

the Eighth People's Hospital of Jinan

dapentidehama@outlook.com+86 13506340918

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026